FR17C1027I1 - - Google Patents
Info
- Publication number
- FR17C1027I1 FR17C1027I1 FR17C1027C FR17C1027I1 FR 17C1027 I1 FR17C1027 I1 FR 17C1027I1 FR 17C1027 C FR17C1027 C FR 17C1027C FR 17C1027 I1 FR17C1027 I1 FR 17C1027I1
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56792104P | 2004-05-03 | 2004-05-03 | |
PCT/US2005/015349 WO2005107712A1 (en) | 2004-05-03 | 2005-05-02 | Liposomes useful for drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
FR17C1027I1 true FR17C1027I1 (uk) | 2017-09-08 |
FR17C1027I2 FR17C1027I2 (fr) | 2020-09-04 |
Family
ID=35320018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR17C1027C Active FR17C1027I2 (fr) | 2004-05-03 | 2017-07-10 | Liposomes utiles pour l'administration de medicaments |
Country Status (20)
Country | Link |
---|---|
US (22) | US8147867B2 (uk) |
EP (3) | EP1746976B1 (uk) |
JP (3) | JP4971142B2 (uk) |
KR (4) | KR101462825B1 (uk) |
CN (3) | CN107811971B (uk) |
AU (1) | AU2005240131C1 (uk) |
CA (4) | CA2928387A1 (uk) |
DK (1) | DK1746976T3 (uk) |
ES (2) | ES2616047T3 (uk) |
FR (1) | FR17C1027I2 (uk) |
HK (2) | HK1200694A1 (uk) |
LU (1) | LUC00026I2 (uk) |
NL (1) | NL300885I2 (uk) |
NO (2) | NO345218B1 (uk) |
PL (1) | PL1746976T3 (uk) |
PT (1) | PT1746976T (uk) |
RU (3) | RU2424792C2 (uk) |
TW (1) | TWI359029B (uk) |
UA (1) | UA86063C2 (uk) |
WO (1) | WO2005107712A1 (uk) |
Families Citing this family (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
CN107811971B (zh) * | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | 用于药物输送的脂质体 |
CA2567857C (en) * | 2004-06-01 | 2009-12-22 | Terumo Kabushiki Kaisha | Irinotecan liposome formulation |
US20080213183A1 (en) * | 2004-09-20 | 2008-09-04 | Marcel Bally | Free or Liposomal Gemcitabine Alone or in Combination with Free or Liposomal Idarubicin |
CA2584279C (en) * | 2004-11-05 | 2015-01-27 | Index Pharmaceuticals Corporation | Compositions and methods for stabilizing liposomal drug formulations |
US8349359B2 (en) * | 2004-11-07 | 2013-01-08 | Your Energy Systems, LLC | Liposomal formulation for oral administration of glutathione (reduced) |
EP1976485A4 (en) * | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR THE PREPARATION OF SAID FORMULATIONS |
DE102006015271A1 (de) * | 2006-04-01 | 2007-10-11 | Lohmann & Rauscher Gmbh & Co. Kg | Biguanidhaltige Liposomen |
US8343539B2 (en) * | 2006-07-14 | 2013-01-01 | Regents Of The University Of Minnesota | Compounds that bind α5β1 integrin and methods of use |
US20080118500A1 (en) * | 2006-11-16 | 2008-05-22 | Taiwan Liposome Company | Sustained releasing composition via local injection for treating eye diseases |
FR2910812B1 (fr) * | 2006-12-29 | 2009-03-20 | Pierre Fabre Medicament Sa | Compositions pharmaceutiques injectables lyophilisees de derives hemi-synthetiques d'alcaloide de vinca stables a temperature ambiante |
CN101209243B (zh) * | 2006-12-29 | 2010-12-08 | 石药集团中奇制药技术(石家庄)有限公司 | 一种脂质体药物及其制备方法 |
WO2008088037A1 (ja) * | 2007-01-18 | 2008-07-24 | National University Corporation Chiba University | 微粒子製剤 |
AU2008227852B2 (en) * | 2007-03-19 | 2011-02-24 | Fresenius Kabi Oncology Ltd. | Proliposomal and liposomal compositions |
US20100173014A1 (en) * | 2007-05-24 | 2010-07-08 | Nanosolutions, Llc | Methods of making and using nano scale particles |
US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
WO2009042114A2 (en) | 2007-09-21 | 2009-04-02 | The Johns Hopkins University | Phenazine derivatives and uses thereof |
JP2011508780A (ja) * | 2008-01-04 | 2011-03-17 | ケラー,ブライアン,チャールズ | 抗真菌薬の増強された送達 |
CN101536981B (zh) * | 2008-03-19 | 2010-11-17 | 上海医药工业研究院 | 一种盐酸可乐定多囊脂质体及其制备方法 |
WO2009138806A1 (en) * | 2008-05-13 | 2009-11-19 | Dendrigen S.A. | Novel liposome cocktail formulations containing doxorubicin and the potent multidrug resistance inhibitor amiodarone |
CA2910133C (en) * | 2008-05-23 | 2018-02-27 | The University Of British Columbia | Modified drugs for use in liposomal nanoparticles |
EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
ES2464729T3 (es) | 2008-08-21 | 2014-06-03 | The Johns Hopkins University | Procedimientos y composiciones para la administración de 3-halopiruvato y compuestos relacionados para el tratamiento del cáncer |
CN101565384B (zh) * | 2008-12-23 | 2012-12-26 | 南开大学 | 环糊精修饰单层石墨及其超分子复合物和制备方法及用途 |
EP2210589B1 (en) * | 2009-01-22 | 2015-05-06 | Ludwig-Maximilians-Universität München | Vesicular phospholipid gels comprising proteinaceous substances |
JP5588619B2 (ja) * | 2009-03-11 | 2014-09-10 | 一丸ファルコス株式会社 | pH応答性リポソーム |
CA2756811C (en) | 2009-03-30 | 2014-09-23 | Eisai R&D Management Co., Ltd. | Liposome composition of eribulin or its pharmacologically permissible salt |
EP2415464B1 (en) * | 2009-03-30 | 2017-05-10 | Eisai R&D Management Co., Ltd. | Method for producing liposome composition |
JP5392707B2 (ja) * | 2009-03-31 | 2014-01-22 | 株式会社Nttドコモ | 膜小胞分裂システム |
US20100298255A1 (en) * | 2009-05-19 | 2010-11-25 | Vivia Biotech S.L. | Methods for providing personalized medicine test ex vivo for hematological neoplasms |
DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
CN102271659B (zh) * | 2009-12-03 | 2013-09-18 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
KR101000358B1 (ko) | 2010-04-29 | 2010-12-13 | 서울대학교산학협력단 | 인테그린 αⅤβ3 결합성 지질 유도체 및 그를 포함하는 지질 나노입자 |
CN105153307A (zh) | 2010-05-04 | 2015-12-16 | 梅里麦克制药股份有限公司 | 抗表皮生长因子受体(egfr)的抗体及其用途 |
US9566238B2 (en) | 2010-06-19 | 2017-02-14 | Western University Of Health Sciences | Formulation of PEGylated-liposome encapsulated glycopeptide antibiotics |
JP6046041B2 (ja) | 2010-10-25 | 2016-12-14 | メドトロニック アーディアン ルクセンブルク ソシエテ ア レスポンサビリテ リミテ | 神経変調療法の評価及びフィードバックのためのデバイス、システム、及び方法 |
US20130302253A1 (en) * | 2011-01-28 | 2013-11-14 | Koninklijke Philips N.V. | Carriers for the local release of hydrophilic prodrugs |
EP2701685A4 (en) * | 2011-04-26 | 2015-04-01 | Cedars Sinai Medical Center | LIPOSOMAL VANCOMYCIN FOR THE TREATMENT OF MRSA INFECTIONS |
EP2717856B1 (en) * | 2011-05-10 | 2016-11-23 | The Penn State Research Foundation | Ceramide anionic liposome compositions |
CN102805729A (zh) * | 2011-06-03 | 2012-12-05 | 齐鲁制药有限公司 | 一种长春氟宁脂质体制剂及其制备方法 |
US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
AU2012326203B2 (en) * | 2011-10-17 | 2017-11-30 | Massachusetts Institute Of Technology | Intracellular delivery |
CN104684579A (zh) | 2012-04-02 | 2015-06-03 | 梅里麦克制药股份有限公司 | 单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用 |
AU2013249307B2 (en) | 2012-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
KR101949125B1 (ko) | 2012-07-04 | 2019-02-18 | 고려대학교 산학협력단 | pH 민감성 형광 발광의 폴리디아세틸렌 리포좀 및 이를 포함하는 약물 전달체 |
WO2014025042A1 (ja) * | 2012-08-10 | 2014-02-13 | 大鵬薬品工業株式会社 | 安定なオキサリプラチン封入リポソーム水分散液及びその安定化方法 |
US9801874B2 (en) | 2012-11-20 | 2017-10-31 | Spectrum Pharmaceuticals | Method for the preparation of liposome encapsulated vincristine for therapeutic use |
RU2514000C1 (ru) * | 2012-12-14 | 2014-04-27 | Общество с ограниченной ответственностью "Уральский центр биофармацевтических технологий" | Липосомальная композиция и способ ее получения |
KR102310786B1 (ko) | 2013-02-01 | 2021-10-12 | 존원 파마, 인코포레이티드 | 리포좀 내로 난수용성 약물의 원격 부하 |
US10828255B2 (en) | 2013-03-05 | 2020-11-10 | The Regents Of The University Of California | Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents |
US9993427B2 (en) * | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
DK2968146T3 (da) * | 2013-03-15 | 2020-03-16 | Taiwan Liposome Co Ltd | Liposomsammensætning med kontrolleret lægemiddelfrigivelse |
US10220095B2 (en) | 2013-03-15 | 2019-03-05 | Taiwan Liposome Company, Ltd | Controlled drug release liposome compositions and methods thereof |
RU2015145135A (ru) * | 2013-04-09 | 2017-05-12 | Крессет Биомолекьюлар Дискавери Лтд | Лечение воспалительных расстройств |
EP2992000B1 (en) | 2013-05-03 | 2020-07-08 | The Regents of The University of California | Cyclic di-nucleotide induction of type i interferon |
SG10201801848UA (en) | 2013-09-11 | 2018-04-27 | Glenn Abrahmsohn | Hypertonic antimicrobial therapeutic compositions |
US20160303264A1 (en) * | 2013-10-23 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for non-invasive imaging and drug delivery |
US9592198B2 (en) * | 2013-10-28 | 2017-03-14 | University Of Maryland, College Park | Microfluidic liposome synthesis, purification and active drug loading |
CA2939916A1 (en) | 2014-02-18 | 2015-08-27 | Glenn Abrahmsohn | Compositions and methods for pain relief without numbness |
JP6276847B2 (ja) * | 2014-04-30 | 2018-02-07 | 富士フイルム株式会社 | リポソーム組成物及びその製造方法 |
PT3138555T (pt) * | 2014-04-30 | 2020-12-15 | Fujifilm Corp | Composição lipossómica e método de produção da mesma |
EP3138557B1 (en) | 2014-04-30 | 2023-06-07 | FUJIFILM Corporation | Liposome composition and method for producing same |
MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
AU2015301234A1 (en) * | 2014-08-04 | 2017-06-15 | Zoneone Pharma, Inc. | Remote loading of sparingly water-soluble drugs into lipid vesicles |
WO2016048242A1 (en) * | 2014-09-24 | 2016-03-31 | Nanyang Technological University | Sustained timolol maleate delivery from liposomes for glaucoma therapy and ocular hypertension |
AU2015360761B2 (en) | 2014-12-09 | 2021-05-20 | Ipsen Biopharm Ltd. | Treatment of breast cancer with liposomal irinotecan |
US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
WO2016191547A1 (en) * | 2015-05-26 | 2016-12-01 | Comfort Care For Animals Llc | Liposome loading |
US9855216B2 (en) * | 2015-05-27 | 2018-01-02 | Ghasem Amoabediny | Targeted nano-liposome co-entrapping anti-cancer drugs |
TWI678213B (zh) | 2015-07-22 | 2019-12-01 | 美商史倍壯製藥公司 | 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物 |
SI3337467T1 (sl) * | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
WO2017034418A1 (en) * | 2015-08-21 | 2017-03-02 | Reynolds John Noble James | Acoustic driven drug delivery systems |
AU2016310476B8 (en) | 2015-08-21 | 2021-10-07 | Ipsen Biopharm Ltd. | Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin |
EP3344575B1 (en) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
DK3349731T3 (da) | 2015-09-16 | 2024-01-08 | Univ Texas | Kombination af topoisomerase-i-inhibitorer med immunoterapi til behandlingen af kræft |
JP6924431B2 (ja) * | 2015-10-13 | 2021-08-25 | 株式会社ケーナインラボ | ヒトを除く哺乳動物への薬剤の投与方法 |
CN105153339B (zh) * | 2015-10-13 | 2017-10-24 | 浙江大学 | 一种氧化响应去正电荷的阳离子聚合物、制备方法和应用 |
US20170319573A1 (en) * | 2015-10-16 | 2017-11-09 | Ipsen Biopharm Ltd. | Stabilizing Camptothecin Pharmaceutical Compositions |
CN114099437A (zh) * | 2015-10-16 | 2022-03-01 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
WO2017078009A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | リポソーム組成物およびその製造方法 |
WO2017078008A1 (ja) * | 2015-11-02 | 2017-05-11 | 富士フイルム株式会社 | ゲムシタビンリポソーム組成物を含む腫瘍治療剤およびキット |
EP3370712A4 (en) | 2015-11-06 | 2019-10-09 | The Johns Hopkins University | METHODS OF TREATING HEPATIC FIBROSIS BY ADMINISTERING 3-BROMOPYRUVATE |
CA3004939A1 (en) | 2015-11-10 | 2017-05-18 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
CN105287264B (zh) * | 2015-11-25 | 2018-06-19 | 上海赢嘉实业有限公司 | 一种包封芳香油复合物的脂质体的制备方法和用途 |
WO2017096361A1 (en) | 2015-12-04 | 2017-06-08 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
CN105496992A (zh) * | 2015-12-08 | 2016-04-20 | 青岛正大海尔制药有限公司 | 氨溴索沙丁胺醇脂质固体分散体 |
WO2017120537A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Mesoporous silica nanoparticles with lipid bilayer coating for cargo delivery |
MA43871A (fr) * | 2016-01-11 | 2018-11-21 | Merrimack Pharmaceuticals Inc | Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées |
MA43870A (fr) | 2016-01-11 | 2021-05-26 | Celator Pharmaceuticals Inc | Inhibition de la protéine associée à l'ataxie télangiectasie et à rad3 (atr) |
CA3014616A1 (en) * | 2016-02-15 | 2017-08-24 | Kemin Industries, Inc. | Water soluble lipophilic materials |
ES2897983T3 (es) * | 2016-02-15 | 2022-03-03 | Univ Georgia | Liposomas cargados con IPA-3 y procedimientos de uso de los mismos |
JP2019508434A (ja) | 2016-03-16 | 2019-03-28 | メリマック ファーマシューティカルズ インコーポレーティッド | エフリン受容体A2(EphA2)標的ドセタキセル産生ナノリポソーム組成物 |
EP3429631A1 (en) | 2016-03-16 | 2019-01-23 | Merrimack Pharmaceuticals, Inc. | Treating ephrin receptor a2 (epha2) positive cancer with targeted docetaxel-generating nano-liposome compositions |
EP3449921B1 (en) | 2016-04-28 | 2023-05-31 | Eisai R&D Management Co., Ltd. | Eribulin for inhibiting tumor growth |
MA45046A (fr) * | 2016-05-18 | 2019-03-27 | Ipsen Biopharm Ltd | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules |
US9655847B1 (en) * | 2016-07-18 | 2017-05-23 | National Guard Health Affairs | Therapeutic liposome and method of treating a subject having cancer |
US10517823B1 (en) | 2016-08-10 | 2019-12-31 | Verily Life Sciences Llc | ROS—responsive liposomes for specific targeting |
US10583083B1 (en) * | 2016-08-10 | 2020-03-10 | Verily Life Sciences Llc | ROS-responsive multilamellar liposomal vesicles for targeting inflammatory macrophages |
US20180236098A1 (en) * | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
CN109789212A (zh) | 2016-08-12 | 2019-05-21 | L.E.A.F.控股集团公司 | 聚谷氨酸化抗叶酸剂及其用途 |
CN109661265A (zh) * | 2016-08-31 | 2019-04-19 | 丘比株式会社 | 蛋黄磷脂组合物及其制造方法、以及使用该蛋黄磷脂组合物的脂肪乳剂及脂解制剂 |
AU2017324718B2 (en) * | 2016-09-09 | 2022-09-29 | Irisys, Inc. | Lipsomal anticancer compositions |
EP3535026A1 (en) | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
US10800817B2 (en) * | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
AU2018210748B2 (en) * | 2017-01-18 | 2023-09-28 | Temasek Life Sciences Laboratory Limited | Hyperstabilized liposomes increase targeting of mitotic cells |
US11510872B2 (en) * | 2017-05-24 | 2022-11-29 | Northwestern University | Nanoparticle-lipid composite carriers and uses thereof |
CN108926719B (zh) * | 2017-05-25 | 2020-09-01 | 北京格瑞特森生物医药科技有限公司 | 用c(RGD-ACP-K)修饰的长循环脂质体 |
KR102444524B1 (ko) * | 2017-09-12 | 2022-09-19 | 오르가노 코포레이션 | 전해액의 정제장치 및 정제방법 |
WO2019054220A1 (ja) * | 2017-09-12 | 2019-03-21 | オルガノ株式会社 | 電解液の精製装置および精製方法 |
CN108047494B (zh) * | 2017-11-15 | 2019-11-08 | 四川大学 | 植酸铵盐阻燃剂及其制备方法和用以制备的阻燃增韧聚乳酸材料 |
CN109364025A (zh) * | 2017-11-17 | 2019-02-22 | 和龙 | 脂质体组合物、其制备方法及其应用 |
EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | PRALATREXATE ALPHA-POLYGLUTAMATE AND ASSOCIATED USES |
US11779584B2 (en) | 2018-02-07 | 2023-10-10 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
WO2019157121A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated lometrexol and uses thereof |
WO2019157123A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
CN111954529A (zh) * | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化氨甲蝶呤及其用途 |
CN111954530A (zh) * | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
CA3090753A1 (en) * | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
CN111971047A (zh) | 2018-02-14 | 2020-11-20 | L.E.A.F.控股集团公司 | γ聚谷氨酸化四氢叶酸及其用途 |
CN111936145A (zh) * | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
WO2020023436A1 (en) * | 2018-07-23 | 2020-01-30 | Campbell Robert B | Cell membrane lipid-extracted nanoparticles (clens) for selective targeting, image analysis and cancer therapy |
CN112512509A (zh) | 2018-08-02 | 2021-03-16 | 台湾微脂体股份有限公司 | 含有治疗抑郁症或焦虑症的治疗剂的缓释组合物及其用途 |
CN112543630B (zh) * | 2018-08-08 | 2023-07-18 | 台湾微脂体股份有限公司 | 含有抗精神病药物的缓释药物组合物及其用途 |
JP7477844B2 (ja) * | 2018-10-17 | 2024-05-02 | タイワン リポソーム カンパニー リミテッド | 免疫調節剤を含む徐放性医薬組成物およびその使用 |
CN109528654B (zh) * | 2018-12-14 | 2021-04-23 | 沈阳药科大学 | 一种盐酸伊立替康和盐酸阿霉素共载脂质体及其制备方法 |
CN109528655A (zh) * | 2018-12-18 | 2019-03-29 | 沈阳药科大学 | 一种双载药脂质体及其制备和应用 |
CN114127267A (zh) | 2019-02-28 | 2022-03-01 | Sqz生物技术公司 | 向pbmc递送生物分子以改变免疫应答 |
CA3136296A1 (en) | 2019-04-08 | 2020-10-15 | Sqz Biotechnologies Company | Cartridge for use in a system for delivery of a payload into a cell |
EP3975995A4 (en) * | 2019-05-28 | 2023-07-19 | Nevakar Injectables Inc. | METHODS AND COMPOSITIONS OF VANCOMYCIN LIPOSOMES |
EP3753549A1 (en) * | 2019-06-20 | 2020-12-23 | InnoMedica Holding AG | Liposomal doxorubicin formulation, method for producing a liposomal doxorubicin formulation and use of a liposomal doxorubicin formulation as a medicament |
WO2021011826A1 (en) * | 2019-07-16 | 2021-01-21 | Coastar Therapeutics Inc. | Process of making membrane lipid coated nanoparticles |
US12036204B2 (en) | 2019-07-26 | 2024-07-16 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
US20230139328A1 (en) * | 2020-03-12 | 2023-05-04 | Aphios Corporation | Dosage forms for improving organ transplantation, graft versus host disease and stem cells transplants |
KR20230052873A (ko) | 2020-06-18 | 2023-04-20 | 아카제라 메디신즈, 인크. | 옥사졸리디논 화합물, 옥사졸리디논 화합물을 포함하는 리포좀 조성물 및 이의 사용 방법 |
CN112190715B (zh) * | 2020-10-21 | 2022-09-30 | 中国人民解放军军事科学院军事医学研究院 | 纳米药物、其制备方法及医药应用 |
WO2022115645A1 (en) | 2020-11-25 | 2022-06-02 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
US11058637B1 (en) * | 2020-11-25 | 2021-07-13 | King Abdulaziz University | Surface-modified emulsomes for intranasal delivery of drugs |
WO2022153211A1 (en) | 2021-01-13 | 2022-07-21 | Sun Pharma Advanced Research Company Limited | Liposomal composition of a camptothecin derivative |
WO2022171777A1 (en) | 2021-02-12 | 2022-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for prognosis and treating a patient suffering from cancer |
KR20240037280A (ko) * | 2021-07-16 | 2024-03-21 | 셀라토 파마슈티칼즈, 인코포레이티드 | 리포솜 제형의 제조 방법 |
WO2023029041A1 (zh) * | 2021-09-06 | 2023-03-09 | 北京茵诺医药科技有限公司 | 靶向动脉粥样硬化脂质体纳米载体递送系统及其制备方法 |
CN117750944A (zh) * | 2021-09-30 | 2024-03-22 | 上海济煜医药科技有限公司 | 一种酒石酸长春瑞滨脂质体及其原料组合物、制备方法和应用 |
EP4169928A1 (en) * | 2021-10-25 | 2023-04-26 | Sandoz Ag | Process for the preparation of sucrose octasulfate octakistriethylammonium salt (tasos) powder and uses thereof |
CN114099691A (zh) * | 2021-11-22 | 2022-03-01 | 京东方科技集团股份有限公司 | 一种人造细胞及其制备方法 |
CA3241030A1 (en) | 2021-12-15 | 2023-06-22 | Daryl C Drummond | Neutrophil exocytosis inhibitors |
CN114306243B (zh) * | 2022-01-07 | 2023-03-28 | 中国人民解放军空军军医大学 | 一种靶向梭型柔性脂质体水凝胶及其制备方法和应用 |
WO2023230587A2 (en) | 2022-05-25 | 2023-11-30 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
CN116602923A (zh) * | 2023-07-20 | 2023-08-18 | 暨南大学附属第一医院(广州华侨医院) | 一种用于关节炎治疗的靶向仿生纳米治疗载体系统 |
Family Cites Families (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192869A (en) * | 1977-09-06 | 1980-03-11 | Studiengesellschaft Kohle Mbh. | Controlled improvement of the O2 release by intact erythrocytes with lipid vesicles |
DE2740053A1 (de) | 1977-09-06 | 1979-05-03 | Klaus Prof Dr Med Gersonde | Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten |
ES473087A1 (es) * | 1977-09-06 | 1979-04-16 | Studiengesellschaft Kohle Mbh | Procedimiento para la preparacion de eritrocitos intactos modificados. |
US4397846A (en) | 1981-05-15 | 1983-08-09 | Murray Weiner | Storage-stable lipid vesicles and method of preparation |
US5059591B1 (en) * | 1983-05-26 | 2000-04-25 | Liposome Co Inc | Drug preparations of reduced toxicity |
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US4649155A (en) | 1983-07-22 | 1987-03-10 | Hoffmann-La Roche Inc. | Injectable solutions |
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US5077056A (en) * | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4755388A (en) | 1984-11-09 | 1988-07-05 | The Regents Of The University Of California | Liposome-encapsulated 5-fluoropyrimidines and methods for their use |
DE3634392A1 (de) | 1986-10-09 | 1988-04-14 | Knoll Ag | Verwendung polysulfatierter niedermolekularer dextransulfate |
MX9203808A (es) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos. |
JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5043165A (en) * | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
US5043164A (en) | 1989-01-17 | 1991-08-27 | The University Of Tennessee Research Corporation | Blood-stable, cholesterol-free liposomes |
US4960790A (en) | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5618798A (en) * | 1989-04-20 | 1997-04-08 | Bar-Shalom; Daniel | Use of sucralfate to treat baldness |
ZA902710B (en) | 1989-05-22 | 1991-12-24 | Univ Georgia Res Found | Enzyme luminescence assay |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
PL296382A1 (en) * | 1991-02-02 | 1993-11-02 | Nika Health Products Ltd Li Li | Artificial membrane beads containing functionally active peptides responsible for fusion as a drug administering system |
US5498420A (en) | 1991-04-12 | 1996-03-12 | Merz & Co. Gmbh & Co. | Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions |
AU654835B2 (en) | 1991-07-03 | 1994-11-24 | Nexstar Pharmaceuticals, Inc. | Loading technique for preparing drug containing liposomes |
US5281237A (en) * | 1992-09-25 | 1994-01-25 | Gimpelson Richard J | Surgical stitching device and method of use |
US5552156A (en) | 1992-10-23 | 1996-09-03 | Ohio State University | Liposomal and micellular stabilization of camptothecin drugs |
US5395619A (en) | 1993-03-03 | 1995-03-07 | Liposome Technology, Inc. | Lipid-polymer conjugates and liposomes |
US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
DE4320597A1 (de) | 1993-06-22 | 1995-01-05 | Heinz C Prof Dr Dr Schroeder | Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren |
US6743917B2 (en) * | 1993-06-30 | 2004-06-01 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
US5534241A (en) * | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
US5538954A (en) * | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
GB9323588D0 (en) | 1993-11-16 | 1994-01-05 | Cortecs Ltd | Hydrophobic preparation |
CN1083713C (zh) * | 1994-02-04 | 2002-05-01 | 利珀克尔集团公司 | 双层制剂 |
US6110481A (en) * | 1994-03-04 | 2000-08-29 | Trustees Of The Stevens Institute Of Technology | Controlled release device based on aqueous-organic partitioning in porous membranes |
US6312719B1 (en) | 1994-03-04 | 2001-11-06 | The University Of British Columbia | Liposome compositions and methods for the treatment of atherosclerosis |
US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
GB9424902D0 (en) | 1994-12-09 | 1995-02-08 | Cortecs Ltd | Solubilisation Aids |
WO1996025147A1 (en) | 1995-02-14 | 1996-08-22 | Sequus Pharmaceuticals, Inc. | Liposome composition and method for administering liposome-loadable drugs |
US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
US5858397A (en) | 1995-10-11 | 1999-01-12 | University Of British Columbia | Liposomal formulations of mitoxantrone |
DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
EP0787716B1 (en) | 1996-01-31 | 1999-12-08 | Nisshin Flour Milling Co., Ltd. | Isoprene derivatives |
US6441025B2 (en) | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
WO1997038010A2 (en) | 1996-04-11 | 1997-10-16 | The University Of British Columbia | Fusogenic liposomes |
US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
CA2269758C (en) * | 1996-10-22 | 2008-01-08 | Hermes Biosciences, Inc. | Liposome compositions comprising ionizable compounds in stable precipitated form and methods for their preparation |
US6210707B1 (en) * | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
ATE318515T1 (de) | 1996-11-19 | 2006-03-15 | Univ Georgetown | Methode zur inhibierung von heregulin und seines rezeptors sowie verwendung zur inhibierung von krebszellen |
US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
JP4386470B2 (ja) * | 1997-05-15 | 2009-12-16 | ユニバーシティ・オブ・ワシントン | アルツハイマー病および他のアミロイド症のための組成物および方法 |
JP2000516641A (ja) * | 1997-07-02 | 2000-12-12 | エスディージー インコーポレイテッド | 診断および治療用途の目標指向性リポソーム構成物 |
US6316612B1 (en) | 1997-08-22 | 2001-11-13 | Ribozyme Pharmaceuticals, Inc. | Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
US6083923A (en) | 1997-10-31 | 2000-07-04 | Isis Pharmaceuticals Inc. | Liposomal oligonucleotide compositions for modulating RAS gene expression |
US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
RU2130771C1 (ru) * | 1998-06-01 | 1999-05-27 | Автушенко Сергей Сергеевич | Способ получения липосомальных препаратов |
US6200598B1 (en) | 1998-06-18 | 2001-03-13 | Duke University | Temperature-sensitive liposomal formulation |
US6726925B1 (en) * | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
GB9813100D0 (en) | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
WO2000009071A2 (en) | 1998-08-11 | 2000-02-24 | All India Institute Of Medical Sciences | A novel liposomal formulation useful in treatment of cancer and other proliferation diseases |
EP1105098B8 (en) | 1998-08-12 | 2007-10-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Liposomal therapeutic compositions an ammonium sulphate gradient prepared using |
ES2198970T3 (es) * | 1998-09-16 | 2004-02-01 | Alza Corporation | Inhibidores de topoisomerasa atrapados en liposomas. |
US6291676B1 (en) * | 1999-03-03 | 2001-09-18 | University Of Kentucky Research Foundation | Water-soluble derivatives of camptothecin/homocamptothecin |
US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
HUP0201644A3 (en) * | 1999-04-29 | 2004-05-28 | Alza Corp Mountain View | Liposome compositions for improved drug retention |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US20020049176A1 (en) * | 1999-11-10 | 2002-04-25 | Anderson Christen M. | Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery |
AU2869901A (en) * | 2000-02-04 | 2001-08-14 | Lipoxen Technologies Limited | Liposomes |
US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
EP1286671B1 (en) | 2000-05-15 | 2006-04-05 | Celgene Corporation | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan |
DE60115045T2 (de) | 2000-06-30 | 2006-08-03 | Inex Pharmaceuticals Corp., Burnaby | Verbesserte liposomale camptothecine und deren verwendungen |
US6486320B2 (en) | 2000-09-15 | 2002-11-26 | Aventis Pharma S.A. | Preparation of camptothecin and of its derivatives |
WO2002036073A2 (en) | 2000-11-02 | 2002-05-10 | Smithkline Beecham Corporation | Receptor antagonist-lipid conjugates and delivery vehicles containing same |
WO2002062316A1 (de) | 2001-02-08 | 2002-08-15 | Vectron Therapeutics Ag | Invasomen zur therapie von erkrankungen, ihre herstellung und verwendung |
EP1385479A4 (en) * | 2001-03-26 | 2006-12-06 | Alza Corp | LIPOSOMIC COMPOSITION FOR IMPROVED INTRA-CELLULAR RELEASE OF A THERAPEUTIC AGENT |
US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
WO2003030864A1 (en) * | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
WO2003028697A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Liposome loading with metal ions |
US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
ITBO20010610A1 (it) * | 2001-10-05 | 2003-04-05 | Haworth S P A | Dispositivo per la connessione di gambe ad elementi di arredamento, ed elemento di arredamento comprendente tale dispositivo |
US20030129224A1 (en) * | 2001-11-13 | 2003-07-10 | Paul Tardi | Lipid carrier compositions and methods for improved drug retention |
CA2467064C (en) | 2001-11-13 | 2011-02-08 | Murray Webb | Lipid carrier compositions with enhanced blood stability |
US20030220284A1 (en) * | 2002-02-22 | 2003-11-27 | Patricia Yotnda | Delivery of adenoviral DNA in a liposomal formulation for treatment of disease |
CA2488230C (en) | 2002-04-29 | 2013-04-09 | Yves Claude Nicolau | Inositol pyrophosphates, and methods of use thereof |
AU2003237864B2 (en) | 2002-05-15 | 2008-12-18 | California Pacific Medical Center | Delivery of nucleic acid-like compounds |
AU2003245160B2 (en) | 2002-06-28 | 2009-09-24 | Arbutus Biopharma Corporation | Method and apparatus for producing liposomes |
US20040243101A1 (en) * | 2002-07-02 | 2004-12-02 | Gillis Edward M. | Minimally invasive drug delivery catheter |
AU2003296897A1 (en) | 2002-08-20 | 2004-05-04 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
AR036316A1 (es) | 2002-08-29 | 2004-08-25 | Monte Verde S A | Una composicion farmaceutica de liposomas de tamano pequeno y metodo de preparacion |
DE10242367A1 (de) | 2002-09-12 | 2004-03-18 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Thermolabiles Liposom mit geregelter Freigabetemperatur |
AU2003298738A1 (en) | 2002-11-26 | 2004-06-18 | Su-Ming Chiang | Liposomal formulations |
JP2007522085A (ja) | 2003-06-27 | 2007-08-09 | スミスクライン・ビーチャム・コーポレイション | 安定化されたトポテカンリポソーム組成物および方法 |
JP2007528854A (ja) * | 2003-07-09 | 2007-10-18 | カリフォルニア パシフィック メディカル センター | 細胞への物質送達の遠隔検出 |
KR20070057701A (ko) | 2004-03-17 | 2007-06-07 | 토카이 유니버시티 에듀케이셔널시스템 | 면역응답 시스템을 이용한 약물전달 시스템 |
US8658203B2 (en) * | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
CN107811971B (zh) | 2004-05-03 | 2021-10-29 | 益普生生物制药公司 | 用于药物输送的脂质体 |
CA2567857C (en) | 2004-06-01 | 2009-12-22 | Terumo Kabushiki Kaisha | Irinotecan liposome formulation |
WO2006002050A1 (en) | 2004-06-15 | 2006-01-05 | Encore Therapeutics, Inc. | Phospholipid compositions and methods for their preparation and use |
PL2572661T3 (pl) * | 2004-10-05 | 2020-06-01 | Genzyme Corporation | Stopniowana kaniula |
US20060129126A1 (en) * | 2004-11-19 | 2006-06-15 | Kaplitt Michael G | Infusion device and method for infusing material into the brain of a patient |
US20060127467A1 (en) | 2004-12-14 | 2006-06-15 | Watkin Kenneth L | Nanoparticles for delivery of therapeutic agents using ultrasound and associated methods |
NZ556541A (en) * | 2004-12-21 | 2011-01-28 | Musc Found For Res Dev | Compositions and methods for promoting wound healing and tissue regeneration using polypetide sequences from an alpha connexin |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US7842676B2 (en) | 2005-10-25 | 2010-11-30 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
EP1976485A4 (en) | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS COMPRISING SECONDARY AND TERTIARY AMINES AND METHODS FOR THE PREPARATION OF SAID FORMULATIONS |
EP2010150A2 (en) | 2006-04-20 | 2009-01-07 | Amgen Inc. | Stable emulsion formulations |
GB0614835D0 (en) | 2006-07-26 | 2006-09-06 | Isis Innovation | Formation of bilayers of amphipathic molecules |
KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Erbb3에 대한 항체 및 이의 용도 |
ES2550759T3 (es) | 2007-08-17 | 2015-11-12 | Celator Pharmaceuticals, Inc. | Formulaciones farmacológicas de platino mejoradas |
US20100239652A1 (en) | 2007-09-28 | 2010-09-23 | Universitatsspital Basel | Immunoliposomes for treatment of cancer |
WO2009059449A1 (en) | 2007-11-05 | 2009-05-14 | Celsion Corporation | Novel thermosensitive liposomes containing therapeutic agents |
US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
WO2016168451A1 (en) | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
SI3337467T1 (sl) | 2015-08-20 | 2021-03-31 | Ipsen Biopharm Ltd. Ash Road | Kombinacijska terapija, ki vsebuje liposomski irinotekan in zaviralec PARP za zdravljenje raka |
CN114099437A (zh) | 2015-10-16 | 2022-03-01 | 易普森生物制药有限公司 | 稳定喜树碱药物组合物 |
US20180110771A1 (en) | 2016-10-21 | 2018-04-26 | Ipsen Biopharm Ltd. | Liposomal Irinotecan Preparations |
US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
EP3535026A1 (en) * | 2016-11-02 | 2019-09-11 | Ipsen Biopharm Limited | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
-
2005
- 2005-05-02 CN CN201710790881.5A patent/CN107811971B/zh active Active
- 2005-05-02 KR KR1020137030020A patent/KR101462825B1/ko active IP Right Grant
- 2005-05-02 CN CN201410025888.4A patent/CN103948545B/zh active Active
- 2005-05-02 CN CN200580022391.6A patent/CN1980637B/zh active Active
- 2005-05-02 ES ES05745505.7T patent/ES2616047T3/es active Active
- 2005-05-02 CA CA2928387A patent/CA2928387A1/en not_active Abandoned
- 2005-05-02 RU RU2006142766/15A patent/RU2424792C2/ru active
- 2005-05-02 PL PL05745505T patent/PL1746976T3/pl unknown
- 2005-05-02 WO PCT/US2005/015349 patent/WO2005107712A1/en active Application Filing
- 2005-05-02 RU RU2011112461D patent/RU2574926C9/ru active
- 2005-05-02 PT PT57455057T patent/PT1746976T/pt unknown
- 2005-05-02 UA UAA200612696A patent/UA86063C2/uk unknown
- 2005-05-02 KR KR1020137004524A patent/KR101462819B1/ko active IP Right Grant
- 2005-05-02 EP EP05745505.7A patent/EP1746976B1/en active Active
- 2005-05-02 JP JP2007511506A patent/JP4971142B2/ja active Active
- 2005-05-02 CA CA3006109A patent/CA3006109A1/en not_active Abandoned
- 2005-05-02 DK DK05745505.7T patent/DK1746976T3/en active
- 2005-05-02 EP EP23165619.0A patent/EP4218730B1/en active Active
- 2005-05-02 ES ES23165619T patent/ES2967961T3/es active Active
- 2005-05-02 EP EP17150833.6A patent/EP3173073A1/en active Pending
- 2005-05-02 AU AU2005240131A patent/AU2005240131C1/en active Active
- 2005-05-02 KR KR1020067025074A patent/KR101223366B1/ko active IP Right Review Request
- 2005-05-02 US US11/121,294 patent/US8147867B2/en active Active
- 2005-05-02 KR KR1020127017425A patent/KR101376895B1/ko active IP Right Grant
- 2005-05-02 CA CA2566007A patent/CA2566007C/en active Active
- 2005-05-02 CA CA2821167A patent/CA2821167C/en active Active
- 2005-05-03 TW TW094114317A patent/TWI359029B/zh active
-
2006
- 2006-11-30 NO NO20065532A patent/NO345218B1/no active Protection Beyond IP Right Term
-
2011
- 2011-12-06 JP JP2011266612A patent/JP5502842B2/ja active Active
-
2012
- 2012-03-09 US US13/416,204 patent/US8329213B2/en active Active
- 2012-10-17 US US13/654,373 patent/US8703181B2/en active Active
-
2013
- 2013-11-22 JP JP2013241469A patent/JP5665950B2/ja active Active
-
2014
- 2014-02-07 US US14/175,365 patent/US8992970B2/en active Active
-
2015
- 2015-01-16 HK HK15100533.7A patent/HK1200694A1/xx unknown
- 2015-02-26 US US14/632,422 patent/US9717723B2/en active Active
- 2015-10-09 US US14/879,358 patent/US20160030342A1/en not_active Abandoned
- 2015-10-09 US US14/879,302 patent/US9730891B2/en active Active
- 2015-12-09 US US14/964,239 patent/US20160081928A1/en not_active Abandoned
- 2015-12-10 US US14/965,140 patent/US9724303B2/en active Active
- 2015-12-11 US US14/966,458 patent/US9782349B2/en active Active
- 2015-12-23 RU RU2015155368A patent/RU2757110C2/ru active
- 2015-12-28 US US14/979,666 patent/US20160106672A1/en not_active Abandoned
-
2016
- 2016-08-03 US US15/227,631 patent/US20160338956A1/en not_active Abandoned
- 2016-08-03 US US15/227,561 patent/US20160339014A1/en not_active Abandoned
- 2016-11-29 US US15/364,021 patent/US20170079914A1/en not_active Abandoned
- 2016-11-29 US US15/363,923 patent/US20170079912A1/en not_active Abandoned
- 2016-11-29 US US15/363,761 patent/US10413510B2/en active Active
- 2016-11-29 US US15/363,978 patent/US10350201B2/en active Active
-
2017
- 2017-07-07 LU LU00026C patent/LUC00026I2/de unknown
- 2017-07-10 FR FR17C1027C patent/FR17C1027I2/fr active Active
- 2017-07-10 NL NL300885C patent/NL300885I2/nl unknown
- 2017-07-31 US US15/664,976 patent/US11052079B2/en active Active
-
2018
- 2018-02-14 US US15/896,436 patent/US20180235954A1/en not_active Abandoned
- 2018-02-14 US US15/896,389 patent/US10722508B2/en active Active
- 2018-09-07 HK HK18111560.7A patent/HK1252167A1/zh unknown
-
2020
- 2020-06-19 US US16/906,601 patent/US20210137914A1/en not_active Abandoned
-
2021
- 2021-01-22 NO NO2021004C patent/NO2021004I1/no unknown
-
2022
- 2022-11-17 US US17/988,857 patent/US20230181567A1/en active Pending